News | January 26, 2009

B&W, Covidien Develop U.S. Source for Key Isotope, May Supply 50 Percent of Demand 


January 27, 2009 - Babcock & Wilcox Technical Services Group Inc. recently signed an agreement with Covidien to develop technology for the manufacture of molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope for molecular imaging and nuclear medicine procedures.

The companies said the program has the potential to supply more than 50 percent of U.S. demand for Mo-99. Under the agreement, B&W and Mallinckrodt Inc., a subsidiary of Covidien, will collaborate on the development of solution-based reactor technology for medical isotope production. The agreement combines Covidien’s expertise in radiopharmaceutical production and global regulatory approvals with B&W’s patented liquid phase nuclear technology. This reactor technology uses low enriched uranium (LEU) and generates only about 1 percent of the radioactive waste compared to spent fuel and processing wastes generated by current reactor production of Mo-99, most of which uses highly enriched uranium.

This collaboration is an initial step toward establishing a large-scale U.S. supply of medical isotopes. Currently, the U.S. imports 100 percent of the Mo-99 supply, which is manufactured at a handful of aging nuclear reactors. Unplanned shutdowns of these reactors for maintenance needs or safety-related issues have led to periodic shortages of medical isotopes. Because Mo-99 has a half-life of only 66 hours, shortages have an almost immediate impact on the ability of physicians to perform critical patient procedures.

About 16 million U.S. patients undergo nuclear medicine procedures to diagnose heart disease or to detect and treat cancer and other medical conditions. Tc-99m, which is derived from Mo-99, is used in about 80 percent of these medical imaging procedures.

For more information: www.babcock.com, www.covidien.com

Related Content

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...
Overlay Init